Cargando…
Safety of etanercept in elderly subjects with rheumatoid arthritis
OBJECTIVE: To report side effects seen in a clinical cohort of patients aged >65 years with rheumatoid arthritis (RA) treated with the tumor necrosis factor-α TNF-α blocker etanercept and to compare the side effects rate with patients aged ≤65 years. METHODS: All patients with RA that started eta...
Autores principales: | Lurati, Alfredomaria, Marrazza, Mariagrazia, Angela, Katia, Scarpellini, Magda |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2819897/ https://www.ncbi.nlm.nih.gov/pubmed/20161980 |
Ejemplares similares
-
NK cell count as predictor of clinical response in patients with rheumatoid arthritis treated with rituximab
por: Lurati, Alfredomaria, et al.
Publicado: (2012) -
Successful Treatment of a Patient with Giant Cell Vasculitis (Horton Arteritis) with Tocilizumab a Humanized Anti-Interleukin-6 Receptor Antibody
por: Lurati, Alfredomaria, et al.
Publicado: (2012) -
The macrophages in rheumatic diseases
por: Laria, Antonella, et al.
Publicado: (2016) -
Calciphylaxis in a patient affected by rheumatoid arthritis, chronic renal failure, and hyperparathyroidism: a case report
por: Lurati, Alfredomaria, et al.
Publicado: (2015) -
Improvement of HbA1c in Patients with Type 2 Diabetes Mellitus and Rheumatoid Arthritis Treated with bDMARDs
por: Lurati, Alfredomaria, et al.
Publicado: (2021)